Also known as: PF-3944 · PF'3944 · PF-08653944 · MET-097 · MET-097i
Berobenatide is an ultra-long-acting, fully biased GLP-1 receptor agonist peptide originally developed by Metsera and advanced by Pfizer following acquisition, designed for once-monthly maintenance dosing after weekly titration — a fourfold reduction in injection frequency versus weekly GLP-1 agonists.
In the Phase 2b VESPER-3 trial, two dosing cohorts of berobenatide reported 10% and 12.3% mean placebo-adjusted weight loss at week 28, with weight loss continuing without a visible plateau. The drug is being developed as a single agent and in combination with an amylin analog (PF-08653945) and a GIPR agonist (MET-034i).
Not yet FDA-approved. Full backbone sequence and molecular weight are not publicly disclosed.
Described in company materials as a "fully biased" GLP-1 receptor agonist — engaging a specific downstream signalling pathway preferentially rather than activating all receptor effectors equally. Patent literature indicates a double fatty-acid acylation strategy that extends albumin-binding half-life enough to support monthly dosing.
Berobenatide (Pfizer/Metsera; also referenced as PF-3944, PF-08653944, and MET-097/MET-097i) is an ultra-long-acting, fully biased GLP-1 receptor agonist peptide originally developed by Metsera and advanced by Pfizer following acquisition. Its defining feature is a double-acylated design (per patent literature) that extends half-life enough to support once-monthly maintenance dosing after an initial weekly titration. In the Phase 2b VESPER-3 trial, two dosing cohorts reported 10% and 12.3% mean placebo-adjusted weight loss at week 28, with a safety profile consistent with the GLP-1 class (predominantly mild-to-moderate GI effects). Full backbone sequence and molecular weight are not publicly disclosed. Also in development in combination with an amylin analog (PF-08653945) and a GIPR agonist (MET-034i).
The once-monthly maintenance design is intended to reduce injection burden versus weekly GLP-1 agonists, not to enable cycling on/off.
Phase 2b / investigational — not an approved medicine. Full molecular structure not publicly disclosed.
Ask anything about Berobenatide — mechanisms, dosing protocols, interactions, or research comparisons.
Semaglutide is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes (Ozempic) and chronic weight management (…
Tirzepatide (Mounjaro/Zepbound) is the first FDA-approved dual GIP/GLP-1 receptor agonist, developed by Eli Lilly. It pr…
AOD-9604 is a modified fragment of human growth hormone (hGH residues 177–191) with an added N-terminal tyrosine residue…
Cagrilintide (AM833) is a long-acting amylin analogue developed by Novo Nordisk. It mimics the satiety and gastric-empty…